Total Payments
$71,947
2024 Payments
$21,308
Companies
7
Transactions
96
Payment Breakdown by Category
Consulting$61,179 (85.0%)
Research$10,707 (14.9%)
Education$45.96 (0.1%)
Food & Beverage$16.18 (0.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $61,179 | 84 | 85.0% |
| Unspecified | $10,707 | 9 | 14.9% |
| Education | $45.96 | 2 | 0.1% |
| Food and Beverage | $16.18 | 1 | 0.0% |
Payments by Type
General
$61,241
87 transactions
Research
$10,707
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ModernaTX, Inc. | $60,382 | 84 | $0 (2024) |
| Horizon Therapeutics plc | $4,026 | 3 | $0 (2022) |
| First Wave BioPharma, Inc. | $3,800 | 3 | $0 (2022) |
| Moderna TX, Inc. | $3,678 | 3 | $0 (2021) |
| Astellas Pharma US Inc | $24.99 | 1 | $0 (2017) |
| Seqirus USA Inc | $20.97 | 1 | $0 (2018) |
| Amgen Inc. | $16.18 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $21,308 | 35 | ModernaTX, Inc. ($21,308) |
| 2023 | $35,845 | 46 | ModernaTX, Inc. ($35,845) |
| 2022 | $8,455 | 7 | Horizon Therapeutics plc ($4,026) |
| 2021 | $6,278 | 5 | Moderna TX, Inc. ($3,678) |
| 2019 | $16.18 | 1 | Amgen Inc. ($16.18) |
| 2018 | $20.97 | 1 | Seqirus USA Inc ($20.97) |
| 2017 | $24.99 | 1 | Astellas Pharma US Inc ($24.99) |
All Payment Transactions
96 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/07/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $877.50 | General |
| 11/07/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $682.50 | General |
| 09/12/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| 09/12/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| 09/12/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $150.00 | General |
| 09/03/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,852.50 | General |
| 09/03/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,268.00 | General |
| 09/03/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $682.50 | General |
| 09/03/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $390.00 | General |
| 08/21/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $780.00 | General |
| 08/21/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $487.50 | General |
| 08/21/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $97.50 | General |
| 07/11/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| 07/11/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| 07/11/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $150.00 | General |
| 06/20/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $195.00 | General |
| 06/20/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $195.00 | General |
| 06/20/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $195.00 | General |
| 05/23/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $293.00 | General |
| 05/23/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $195.00 | General |
| 04/29/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| 03/21/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $293.00 | General |
| 03/21/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $195.00 | General |
| 02/29/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $293.00 | General |
| 02/22/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $150.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Niclosamide | First Wave BioPharma, Inc. | $3,800 | 3 |
| A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age | ModernaTX, Inc. | $1,668 | 1 |
| A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose Confirmation Study to Evaluate the Safety, Tolerability, and Immunogenicity of Lyophilized Zika Vaccine mRNA-1893 in Adults Aged 18-65 Years and Living in Endemic and Non Endemic Flavivi | Moderna TX, Inc. | $1,365 | 1 |
| A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | Moderna TX, Inc. | $1,263 | 1 |
| A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age | ModernaTX, Inc. | $1,073 | 1 |
| A Phase 1, Randomized, Observer-Blind, Placebo-Controlled,Dose Escalation Study to Evaluate the Safety, Reactogenicity,and Immunogenicity of mRNA-1345, an mRNA VaccineTargeting Respiratory Syncytial Virus (RSV), in HealthyYounger Adults Aged | Moderna TX, Inc. | $1,050 | 1 |
| A Study to Evaluate the Safety and Immunogenicity of the mRNA-1273.214 COVID-19 Vaccine in Healthy Children Between 6 Months to Less Than 6 Years of Age | ModernaTX, Inc. | $488.00 | 1 |
About Dr. Michael Polis, M.D
Dr. Michael Polis, M.D is a Infectious Disease healthcare provider based in Bethesda, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/17/2010. The National Provider Identifier (NPI) number assigned to this provider is 1821316704.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Polis, M.D has received a total of $71,947 in payments from pharmaceutical and medical device companies, with $21,308 received in 2024. These payments were reported across 96 transactions from 7 companies. The most common payment nature is "Consulting Fee" ($61,179).
Ad
Practice Information
- Specialty Infectious Disease
- Location Bethesda, MD
- Active Since 05/17/2010
- Last Updated 05/17/2010
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1821316704
Products in Payments
- Aimovig (Biological) $16.18
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Bethesda
Dr. Jesse Goodman, M.d., M.p.h, M.D., M.P.H
Infectious Disease — Payments: $2.7M
Infectious Disease $2.7M
Caryn Morse, M.d., M.p.h, M.D., M.P.H
Infectious Disease — Payments: $19,701
Infectious Disease $19,701
Amy Klion, Md, MD
Infectious Disease — Payments: $5,389
Infectious Disease $5,389
Dr. James Moon, M.d, M.D
Infectious Disease — Payments: $2,644
Infectious Disease $2,644
Dr. Trevor Crowell, M.d, M.D
Infectious Disease — Payments: $480.55
Infectious Disease $480.55
Dr. William Davis, Md, MD
Infectious Disease — Payments: $452.12
Infectious Disease $452.12